The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2009Plasma Biomarker Screen for Neurodegeneration and Signaling Proteins
Objective/Rationale:
The cells and tissues of the body can “communicate” with one another using small secreted proteins that can be found in the blood. There are several hundred of these cellular... -
Therapeutic Pipeline Program, 2020Dual-task Augmented Reality Treatment (DART) Protocol for Parkinson’s Disease
Study Rationale:
Approximately 80 percent of people with Parkinson’s disease fall due to problems with posture, walking and balance, known as postural and gait dysfunction (PIGD) one or more times a... -
Critical Challenges in PD: Alpha-synuclein Neuroimaging, 2009Utility of the Amyloid Ligand [18F]FDDNP in Human PET Imaging in Parkinson Disease
Objective/Rationale:
Biomarkers of Parkinson disease are sorely needed for the assessment of disease status so that they may be used to design more efficient and informative clinical trials of disease... -
PD Subtypes, 2007Do Clinical Characteristics at PD Diagnosis Predict Survival?
Tremendous efforts have been directed toward the identification of factors that affect the progression of Parkinson's disease, yet to date few factors have been identified. Most studies seeking to...
-
PPMI Sample Request, 2014Whole Blood RNA Biomarkers of Parkinson’s Disease
Objective/Rationale:
When a Parkinson’s disease patient first experiences motor symptoms, most of the neurons in the part of the brain affected by the disease have already died and therefore the... -
Resource: Utilizing DATATOP Biospecimens, 2011Validation of Alpha-synuclein Oligomers as Biomarker for Parkinson’s Disease
Objective/Rationale:
We have reported recently higher levels of α-synuclein oligomers species in cerebral spinal fluid (CSF) from patients clinically diagnosed with Parkinson’s disease (PD) versus...
![Two female doctors talking in the lab.](/sites/default/files/styles/ad_callout_single/public/images/ad/apply-for-grant-404-Large-Image-Callout-A-1.jpg?h=2a1ad497&itok=bH9DMhdC)
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.